Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB06073_nanopub.RAZ08k0kqWar3vxZGD4hK8WmeDVlCX_V7fU-mL0sYyJC8#assertion>. }
Showing items 1 to 12 of
12
with 100 items per page.
- drugbank:DB06073 type drugbank_vocabulary:Drug assertion.
- drugbank:DB06073 label "CTS-21166 [drugbank:DB06073]" assertion.
- drugbank:DB06073 seeAlso DB06073 assertion.
- drugbank:DB06073 description "CTS-21166 is a small-molecule beta-secretase inhibitor, which is being developed as a disease-modifying treatment for Alzheimer's disease. CTS-21166 is the only BACE1 inhibitor that has passed Phase I clinical trial thus far. In 2008, CoMentis revealed this small compound as a transition-state analog inhibitor (structure is currently undisclosed) with excellent properties in brain penetration, selectivity, metabolic stability, and oral availability; all of these have met the requirements of an ideal oral drug candidate." assertion.
- drugbank:DB06073 identifier "drugbank:DB06073" assertion.
- drugbank:DB06073 title "CTS-21166" assertion.
- drugbank:DB06073 drugbank_vocabulary:x-cas cas: assertion.
- drugbank:DB06073 drugbank_vocabulary:drugbank-id "DB06073" assertion.
- drugbank:DB06073 bio2rdf_vocabulary:x-identifiers.org DB06073 assertion.
- drugbank:DB06073 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB06073" assertion.
- drugbank:DB06073 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB06073 bio2rdf_vocabulary:identifier "DB06073" assertion.